In previously untreated patients with mTNBC, what is your protocol for prophylactic GCSF use for sacituzumab govitecan?

Sacituzumab govitecan (SG) causes grade 3 or higher neutropenia in 47% of patients and neutropenic fever in 7%. It has a boxed warning for neutropenia and recommends primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) for all patients at increased risk of febrile neutropenia. Fata...

I use long-acting G-CSF on day 9, and occasionally use short-acting G-CSF on days 3 and 4 if day 8 ANC tends to be too low (< 1,000).

For previously untreated patients with mTNBC, neutropenia remains a clinically meaningful adverse event that can delay or interrupt scheduled therapy. In the pivotal sacituzumab govitecan (SG) trials, grade ≥3 neutropenia was reported in approximately 51% of patients in the second-line ASCENT study,...